Viridian Therapeutics (NASDAQ:VRDN) Trading 4.9% Higher

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares traded up 4.9% on Monday . The stock traded as high as $13.20 and last traded at $13.19. 97,024 shares were traded during trading, a decline of 90% from the average session volume of 958,474 shares. The stock had previously closed at $12.57.

Analysts Set New Price Targets

A number of analysts have commented on VRDN shares. Oppenheimer reduced their target price on Viridian Therapeutics from $36.00 to $31.00 and set an “outperform” rating for the company in a report on Thursday, May 9th. LADENBURG THALM/SH SH lowered Viridian Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, May 9th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Viridian Therapeutics in a report on Tuesday, June 11th. B. Riley lowered Viridian Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $25.00 to $20.00 in a report on Thursday, May 9th. Finally, HC Wainwright dropped their price target on shares of Viridian Therapeutics from $37.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Viridian Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Viridian Therapeutics Stock Up 4.3 %

The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.99 and a current ratio of 23.99. The company has a fifty day moving average of $13.35 and a two-hundred day moving average of $17.20. The company has a market cap of $836.68 million, a PE ratio of -2.79 and a beta of 1.03.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.28. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.09 million. Viridian Therapeutics had a negative return on equity of 92.04% and a negative net margin of 75,737.85%. Viridian Therapeutics’s quarterly revenue was down 26.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.61) earnings per share. As a group, analysts anticipate that Viridian Therapeutics, Inc. will post -3.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

Institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its position in Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares during the period. Swiss National Bank boosted its position in Viridian Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 67,200 shares of the company’s stock valued at $1,464,000 after purchasing an additional 800 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Viridian Therapeutics by 9.7% in the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after buying an additional 1,058 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Viridian Therapeutics by 4.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after acquiring an additional 1,135 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its position in Viridian Therapeutics by 9.7% during the fourth quarter. New York State Common Retirement Fund now owns 17,495 shares of the company’s stock valued at $378,000 after acquiring an additional 1,545 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.